Tenaya Therapeutics, Inc. (TNYA)

NASDAQ: TNYA · IEX Real-Time Price · USD
10.00 -0.01 (-0.10%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap412.81M
Revenue (ttm)n/a
Net Income (ttm)-56.89M
Shares Out41.28M
EPS (ttm)-7.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume125,490
Open9.72
Previous Close10.01
Day's Range9.22 - 10.09
52-Week Range9.25 - 32.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About TNYA

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with both rare and highly prevalent forms of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and University of Texas Southwestern Medical Center, we are dev...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOFaraz Ali, M.B.A.
Employees100
Stock ExchangeNASDAQ
Ticker SymbolTNYA
Full Company Profile

Financial Performance

Financial Statements

News

Tenaya Therapeutics Provides 2022 Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics provided a 2022 business update.

5 days ago - Business Wire

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced changes to its Board of Directors.

1 month ago - Business Wire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in the 33rd Annual Piper Sandler Healthcare Conference.

1 month ago - Business Wire

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today reported business and program updates and third quarter 2021 financial results.

2 months ago - Business Wire

Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that it will present new preclinical data at the ESGCT 28th Annual Congress.

3 months ago - Business Wire

Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in upcoming investor and industry conferences.

3 months ago - Business Wire

Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics reported business and program updates and second quarter 2021 financial results.

4 months ago - Business Wire

Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics announced that it will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.

4 months ago - Business Wire

Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Op...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. announced today the closing of its underwritten, upsized initial public offering.

5 months ago - Business Wire

Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. announced today the pricing of its underwritten, upsized initial public offering.

5 months ago - Business Wire